Identification of Single Biomolecules Could Soon Be Even Faster
|
By LabMedica International staff writers Posted on 08 Feb 2016 |
Scientists have developed a breakthrough new method that may soon enable the capture of individual biological molecules 1,000 times faster, leading to more efficient research and diagnostic detection for important medical conditions.
Gathering and identifying molecules for analysis can be done by passing molecules in solution through a nanopore and detecting the change in electric current the molecules create. The problem with this technique, “nanopore sensing,” is that it is usually diffusion-limited, and so relies on molecules drifting close to the nanopore before being captured.
Now, a team led by researchers at Imperial College London (London, UK) in collaboration with colleagues at University of Minnesota (Minneapolis – St. Paul; MN; USA) have demonstrated a technique to attract molecules towards the nanopore, making the process up to 1,000 times more efficient.
“By pulling molecules towards the detector instead of relying purely on diffusion, we can access a much larger volume, and by doing so can detect the same number of molecules from a much smaller concentration,” said senior author Dr. Joshua Edel from Imperial, “What might currently take 5 hours to analyze could be done in a couple of minutes with our new method.”
The technique, “single molecule dielectrophoretic trapping,” will also allow for analysis of very dilute samples. Capability to analyze molecules in low-concentration samples could be particularly important when looking for evidence of epigenetic modifications such as DNA methylation. The team tested their method with DNA molecules, but said it could be modified to detect a wide range of medically important molecules, from proteins to whole cells.
The technique uses an electrically-charged nano-pipette that exerts an electrical attraction force on the molecule that draws it close to the pipette tip, the nanopore. The shape and minute size of the tip, less than 50 nanometres, enables detection of single molecules.
Detecting and analyzing each molecule individually also avoids the problem of averaged results that obscure rare, but possibly important, events. “We can now capture needle-in-a-haystack events,” said coauthors Dr. Aleksandar Ivanov and Dr. Kevin Freedman of Imperial. “The huge increase in efficiency brought about by this technique paves the way for high-speed and high-throughput detection of rare events in ultra-dilute samples.” The team has filed a patent for their invention and expect that it will have application implications in the near future.
The study, by Freedman KJ et al., was published 2016, in the journal Nature Communications.
Related Links:
Imperial College London
University of Minnesota
Gathering and identifying molecules for analysis can be done by passing molecules in solution through a nanopore and detecting the change in electric current the molecules create. The problem with this technique, “nanopore sensing,” is that it is usually diffusion-limited, and so relies on molecules drifting close to the nanopore before being captured.
Now, a team led by researchers at Imperial College London (London, UK) in collaboration with colleagues at University of Minnesota (Minneapolis – St. Paul; MN; USA) have demonstrated a technique to attract molecules towards the nanopore, making the process up to 1,000 times more efficient.
“By pulling molecules towards the detector instead of relying purely on diffusion, we can access a much larger volume, and by doing so can detect the same number of molecules from a much smaller concentration,” said senior author Dr. Joshua Edel from Imperial, “What might currently take 5 hours to analyze could be done in a couple of minutes with our new method.”
The technique, “single molecule dielectrophoretic trapping,” will also allow for analysis of very dilute samples. Capability to analyze molecules in low-concentration samples could be particularly important when looking for evidence of epigenetic modifications such as DNA methylation. The team tested their method with DNA molecules, but said it could be modified to detect a wide range of medically important molecules, from proteins to whole cells.
The technique uses an electrically-charged nano-pipette that exerts an electrical attraction force on the molecule that draws it close to the pipette tip, the nanopore. The shape and minute size of the tip, less than 50 nanometres, enables detection of single molecules.
Detecting and analyzing each molecule individually also avoids the problem of averaged results that obscure rare, but possibly important, events. “We can now capture needle-in-a-haystack events,” said coauthors Dr. Aleksandar Ivanov and Dr. Kevin Freedman of Imperial. “The huge increase in efficiency brought about by this technique paves the way for high-speed and high-throughput detection of rare events in ultra-dilute samples.” The team has filed a patent for their invention and expect that it will have application implications in the near future.
The study, by Freedman KJ et al., was published 2016, in the journal Nature Communications.
Related Links:
Imperial College London
University of Minnesota
Latest Molecular Diagnostics News
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
- Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
- Gene Fusion Patterns May Flag High Risk Solitary Fibrous Tumors
- New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders
- FDA Approves Expanded Liquid Biopsy Panel for Advanced Cancer Profiling
- Microbial Saliva Test Could Help Triage Esophageal Cancer Risk
- Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing
- Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer
- Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
- New Computational Tool Reveals Genetic Driver of Idiopathic Neuropathy
- Breast Cancer-Specific Signatures Link Genome Instability to Outcomes
- FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors
- ctDNA Blood Test Could Help Guide Radiotherapy in Patients with Limited Metastases
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








